TriME® Platform
- Fully human antibody with controllable affinity, low immunogenicity, and natural IgG-like conformation to enhance safety and reduce immune risk.
- CD3ε as the cornerstone for precise T-cell engagement, with an optimized affinity window that balances potent cytotoxicity with reduced off-target activation.
- Modular bi-/tri-specific architecture allows flexible Fab combinations, adaptable to a broad range of T-cell engager designs.
- Superior safety margin demonstrated by lower cytokine release in vitro compared to traditional high-affinity scFv CD3 antibodies.
- Efficient and durable T-cell activation through formation of strong immune synapses, supporting persistent and effective tumor cell killing.
- Low CMC risk from optimized chain pairing and stable structure, enabling high yield and consistent quality.
- GMP-validated manufacturability for rapid IND readiness and clinical progression.
- Formulation flexibility, including subcutaneous administration, to improve patient compliance and support long-term treatment.
